Bispecific antibodies in cancer therapy: Target selection and regulatory requirements

Yanze SUN; Xinmiao YU; Xiao WANG; Kai YUAN; Gefei WANG; Lingrong HU; Guoyu ZHANG; Wenli PEI; Liping WANG; Chengliang SUN; Peng YANG.
Acta Pharmaceutica Sinica B ; (6): 3583-3597, 2023.
Artículo en Inglés | WPRIM | ID: wpr-1011142

Documentos relacionados

  1. Bispecific antibodies in cancer therapy: Target selection and regulatory requirements.
  2. Biomedical research in france and brazil: an analysis of significant differences and ethical issues
  3. [Intrathecal baclofen therapy: a 30-year experience].
  4. [Low level laser therapy: molecular mechanisms of anti-inflammatory and regenerative effects].
  5. [Periinterventional antiplatelet therapy: from bench to bedside].
  6. [Healthcare Research into Anti-VEGF Therapy: Selection and Methodological Precautions].
  7. [Online schema therapy: a cross-sectional survey among Dutch therapists].
  8. [Health service aspects of electroconvulsive therapy: analysis of external referrals to a university medical center].
  9. [The benefit of new angiogenesis (bevacizumab and aflibercept) inhibitors for multiple angiomatosis therapy: a case report].
  10. [Biotechnological advances in monoclonal antibody therapy: the RANK ligand inhibitor antibody].